MARKET
IPO

ALZH

ALZHEON, INC.
ALZH
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-6.70
-
1.43
81.34M
Biotechnology & Medical Research
2018-08-27
Public Filing
View Prospectus
Pending
Offering
Price Range: 13.00~15.00
Shares to be Issued: 6000.00K
Pending
Offering End Date
Offering Price: 5.00
Post IPO Outstanding: 16.27M
Listed
No Data
About ALZH
Alzheon, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on brain health, memory and aging, and develops treatments for Alzheimer's disease and other neurodegenerative disorders. The Company's product candidate, ALZ-801 targets formation of amyloid that affects the brains of patients with Alzheimer's disease. ALZ-801 is an orally administered inhibitor of beta amyloid misfolding. It is an orally bioavailable small molecule prodrug of tramiprosate, which targets soluble amyloid-b peptides and prevents pathological aggregation and neurotoxicity that leads to neuronal cell loss and clinical decline of patients with Alzheimer's disease.

Webull offers ALZHEON, INC. stock information, including NASDAQ: ALZH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALZH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALZH stock methods without spending real money on the virtual paper trading platform.